Q-omics provides the consensus-scored ATP5PO profile across patient tissues and cancer cell-line models. ATP5PO expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP5PO is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ATP5PO protein abundance shows 23,355 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where ATP5PO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PO survival associations across molecular data types. ATP5PO RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PO RNA expression–survival associations across cancer types. High ATP5PO expression shows unfavorable associations in UVM, SCLC, ACC, LIHC and LAML, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP5PO RNA expression.
This table summarizes ATP5PO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATP5PO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PO shows lower tumor expression in HNSC, COAD, STAD, THCA and KIRC and higher tumor expression in LIHC. The HNSC box plot shows higher ATP5PO RNA expression in normal versus tumor tissue (log2 FC = −0.432, t-test p < 0.001).
This table shows molecular features associated with ATP5PO in patient tissues and cancer cell lines. In patient samples, ATP5PO shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5PO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
